Arcturus Therapeutics to Present at the Following Investor Conferences in November

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The Company will host a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 2:45 p.m. ET, and present at the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:30 a.m. ET. Arcturus focuses on developing mRNA medicines targeting infectious diseases and rare liver and respiratory conditions.

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences.

Guggenheim 4^th Annual Immunology and Neurology Day (Fireside Chat)

• Tuesday, November 15, 2022 (2:45 p.m. ET)

34^th Annual Piper Sandler Healthcare Conference (Presentation)

• Tuesday, November 29, 2022 (11:30 a.m. ET)

If available, links can be found under the Investor Relations/Events section of the Arcturus’ website.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, self-amplifying RNA, antisense RNA, circular RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107006097/en/

IR and Media Contacts

Arcturus Therapeutics

IR@arcturusrx.com

Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

Source: Arcturus Therapeutics Holdings Inc.

FAQ

What is Arcturus Therapeutics' schedule for investor conferences in November 2022?

Arcturus Therapeutics will participate in two conferences: the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 2:45 p.m. ET, and the 34th Annual Piper Sandler Healthcare Conference on November 29, 2022, at 11:30 a.m. ET.

What is the ticker symbol for Arcturus Therapeutics?

The ticker symbol for Arcturus Therapeutics is ARCT.

Where is Arcturus Therapeutics headquartered?

Arcturus Therapeutics is headquartered in San Diego, California.

What are Arcturus Therapeutics' main areas of focus?

Arcturus Therapeutics focuses on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases.

How can I find more information about Arcturus Therapeutics' investor events?

Information about Arcturus Therapeutics' investor events can be found on their website under the Investor Relations/Events section.